Zoetis Inc. $ZTS Shares Acquired by GC Wealth Management RIA LLC

Key Points

• GC Wealth Management RIA LLC increased its stake in Zoetis Inc. by 143.4% during Q2, now owning 8,352 shares valued at $1.3 million.
• Zoetis reported Q2 earnings of $1.76 per share, exceeding estimates, with revenues of $2.46 billion, a 4.2% increase year-over-year.
• The stock currently has an average rating of "Moderate Buy" among analysts, with an average price target of $200.88.

GC Wealth Management RIA LLC lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 143.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,352 shares of the company's stock after buying an additional 4,920 shares during the period. GC Wealth Management RIA LLC's holdings in Zoetis were worth $1,302,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. AdvisorNet Financial Inc grew its stake in Zoetis by 23.0% during the 1st quarter. AdvisorNet Financial Inc now owns 1,642 shares of the company's stock worth $270,000 after buying an additional 307 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its position in Zoetis by 14.7% during the first quarter. Fifth Third Wealth Advisors LLC now owns 8,521 shares of the company's stock worth $1,403,000 after buying an additional 1,095 shares during the period. Czech National Bank increased its position in Zoetis by 5.1% during the first quarter. Czech National Bank now owns 102,850 shares of the company's stock worth $16,934,000 after buying an additional 5,028 shares during the period. Finally, Baker Tilly Wealth Management LLC lifted its stake in Zoetis by 4.0% in the first quarter. Baker Tilly Wealth Management LLC now owns 2,163 shares of the company's stock valued at $356,000 after buying an additional 83 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.4%

ZTS stock opened at $142.97 on Tuesday. The stock has a market capitalization of $63.36 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 2.30 and a beta of 0.88. The company has a fifty day moving average of $150.26 and a 200-day moving average of $155.52. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a one year low of $139.34 and a one year high of $196.55.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, Argus reissued a "buy" rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.